

(19) World Intellectual Property Organization
International Bureau






(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082812 A2

- (51) International Patent Classification⁷: C07C 303/22, 309/66
- (21) International Application Number: PCT/GB03/01395
- (22) International Filing Date: 28 March 2003 (28.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201005-6 2 April 2002 (02.04.2002) SE
- (71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).
- (71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **LARSSON, Maria** [SE/SE]; AstraZeneca R & D Sodertalje, S-151 85 Sodertalje (SE).
- (74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: NEW PROCESS



(57) Abstract: A process for the preparation of a compound of formula (I); in which R represents H or an acid protecting group which comprises reacting a compound of formula (II); in which R is as previously defined with a compound of formula (III); wherein X is a suitable leaving group in the presence of a base and using water as a diluent.

NEW PROCESS

The present invention relates to an improved process for the preparation of the compound 2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, as shown
5 in formula I below



10 or the (R) or the (S) enantiomer thereof, or a pharmaceutically-acceptable salt thereof, and solvates thereof.

The above compound is intended for therapeutic use in the Insulin Resistance Syndrome (IRS) including type 2 diabetes mellitus, which refers to a cluster of manifestations
15 including insulin resistance with accompanying hyperinsulinaemia, possible type 2 diabetes mellitus, arterial hypertension, central (visceral) obesity, dyslipidaemia observed as deranged lipoprotein levels typically characterised by elevated VLDL (very low density lipoproteins), small dense LDL particles and reduced HDL (high density lipoprotein) concentrations and reduced fibrinolysis.

20

Recent epidemiological research has documented that individuals with insulin resistance run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering from myocardial infarction and stroke. In type 2 diabetes mellitus atherosclerosis related conditions cause up to 80% of all deaths.

25


In clinical medicine there is awareness of the need to increase the insulin sensitivity in IRS suffering patients and thus to correct the dyslipidaemia which is considered to cause the

accelerated progress of atherosclerosis. However, currently this is not a universally well defined disease.


The compound of formula I is disclosed in PCT Publication Number WO99/62872. Two
5 alternative processes are disclosed for the preparation of the compound of formula I in Examples 1 and 2 of the application. We have discovered an improvement in relation to one of the processes disclosed.

Specifically we have found an improved method for the synthesis of the penultimate
10 esterified intermediate, the final step of the reaction being the conversion of the ester group into the acid of the final product.


Accordingly the present invention provides a process for the preparation of a compound of formula I



in which R represents H or an acid protecting group which comprises reacting a compound
of formula II



in which R is as previously defined with a compound of formula III



wherein X is a suitable leaving group in the presence of a base using water as the diluent.

Suitably the process is carried out at a temperature in the range 0°C to 250°C and preferably in the range 50°C to 150°C. More preferably the process is carried out at a temperature in the range of 80°C to 130°C and most preferably in the range of 90°C to 110°C.

The term "acid protecting group" means that the acid is protected from reaction by forming a suitable acid derivative such as an ester or amide or by other means of protection of carboxylic acid groups known in the art. Examples of suitable means of protection and acid derivatives (as well as means of formation and eventual deprotection), may be found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Third Edition, John Wiley & Sons, New York, 1999. The nature of the ester is not important in the performance of the process since its function is to act as a protecting group. The improvements relate to the application of phase transfer catalysis to the process. Preferably R is H, benzyl or a (1-4C)alkyl group, such as methyl, ethyl or propyl. More preferably R is a (1-4C)alkyl group. Most preferably R is ethyl.

Suitably X is halo, for example bromo, chloro or iodo, an optionally substituted phenylsulfonyloxy group, in particular (4-methylphenyl)sulfonyloxy group or 2,4,6-triisopropylphenylsulfonyloxy group or an alkylsulphonyloxy group for example methanesulphonyloxy. Preferably X is a methanesulphonyloxy group.

Suitable bases include carbonates, hydrogen carbonates or hydroxides particularly of alkali metals. Preferably the base is sodium carbonate, sodium hydrogen carbonate, potassium carbonate or potassium hydrogen carbonate.


- 5 Suitably the molar ratio of the compound of formula III to the compound of formula II is in the range of 0.5 to 10, preferably in the range 0.8 to 4 and more preferably in the range of 1.0 to 3 and most preferably is in the range of 1.2 to 1.8 for example 1.2 to 1.6.

- 10 Suitably the molar ratio of the base to the compound of formula II is in the range of 0.5 to 10, preferably in the range 0.8 to 7 for example 0.8 to 4 and more preferably in the range of 1.0 to 5 and most preferably is in the range of 1.2 to 4.2.


- The process of the invention has the following advantages. The reaction times are more rapid than the reactions known in the prior art and therefore the process is less costly to run. In addition the process gives higher yields and the product is of a higher purity than previously disclosed processes for the preparation of the compound of formula I. Also, it is a considerable advantage in terms of waste disposal, environmental reasons and cost to use water as the diluent instead of an organic liquid. Further, the process is consistently reproducible and robust.

- 20 Converting the acid ester derivative may be accomplished simply by hydrolysis (acidic or alkaline or enzymatic) of the ester to the acid, such a step being known to the skilled person, such as described in the examples below and in Example 2 i) of WO99/62872.


- 25 In another aspect the present invention provides a process for the preparation of a compound of formula I



in which R represents H which comprises reacting a compound of formula II



in which R represents an acid protecting group with a compound of formula III



wherein X is a suitable leaving group in the presence of a base and using water as the diluent to give a compound of formula I in which R is an acid protecting group and then removing the protecting group to give a compound of formula I in which R is H.

In a preferred aspect the protecting group is an ester and the protecting group removal step comprises a hydrolysis step. The hydrolysis step may be acid or base catalysed. Preferably the base is lithium hydroxide. Optionally an organic liquid may be present in the hydrolysis step for example acetone, 2-butanone, methanol, ethanol, tetrahydrofuran or dioxane.

In a preferred aspect the process provides the S-enantiomer of the compound of formula I in which R is H by using the S-enantiomer of the compound of formula II in which R represents H or an acid protecting group followed by hydrolysis when R is an acid protecting group.

The compound of formula I in which R is H may be purified by recrystallisation. Suitable recrystallisation solvents include one or more of the following ethanol, water, isopropyl acetate, isopropanol, isooctane and toluene.

The invention is illustrated by the following non-limiting examples.

Abbreviations

- 5 EtOAc = ethyl acetate
HPLC = high-pressure liquid chromatography
i-PrOAc = isopropyl acetate
EtOH = ethanol

10 Preparation of Starting Material

2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate was prepared as described in WO99/62872.


15 Example 1

(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid


- A mixture of 2-(4-methanesulfonyloxyphenyl)ethylmethanesulfonate (9.88 g / 33.57mmol), ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (5.0 g / 20.98 mmol),
20 Na₂CO₃ (2.96 g / 27.9 mmol eq) and water (10ml) was boiled under reflux with vigorous stirring for 4.5 h. The mixture was cooled to 2°C and acetone (13.5ml) was added. The mixture containing ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxy-phenyl}ethoxy)phenyl] propanoate was allowed to warm up to ambient temperature. The acetone solution was kept at T_i = 25 °C in the reactor. LiOH·H₂O powder (1.144 g /
25 27.27mmol) dissolved in water (20ml) was charged continuously over 30 minutes under vigorous stirring at 25±5 °C. The reaction was continued for 7 hours. The reaction was quenched by addition of EtOAc (1.5 ml) at T_i = 25±5 °C. Acetic acid was added to the water mixture after phase-separation and the pH was corrected to 1-3 using sulphuric acid in water. The crude title compound was crystallized by seeding. The identity of the product
30 was confirmed by HPLC and gave a relative area of 76%.

Claims


1. A process for the preparation of a compound of formula I



5 in which R represents H or an acid protecting group which comprises reacting a compound of formula II




10 in which R is as previously defined with a compound of formula III




wherein X is a suitable leaving group in the presence of a base and using water as a diluent.


15 2. A process for the preparation of a compound of formula I



in which R represents H which comprises reacting a compound of formula II



5 in which R represents an acid protecting group with a compound of formula III



wherein X is a suitable leaving group in the presence of a base and using water as the diluent to give a compound of formula I in which R is an acid protecting group and then removing the protecting group to give a compound of formula I in which R is H.

3. A process according to claim 2 in which the acid protecting group is removed by hydrolysis.

4. A process according to any preceding claim in which R is H, benzyl or a (1-4C)alkyl group.

5. A process according to any preceding claim in which X is halo, an optionally substituted phenylsulfonyloxy group or an alkylsulphonyloxy group.

6. A process according to any preceding claim in which the base is selected from carbonates, hydrogen carbonates or hydroxides of alkali metals.

7. A process according to any preceding claim in which the compound of formula I is the S enantiomer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)




PCT

(10) International Publication Number
WO 2003/082812 A3

- (51) International Patent Classification⁷: **C07C 303/22**, 309/66
- (21) International Application Number: **PCT/GB2003/001395**
- (22) International Filing Date: 28 March 2003 (28.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0201005-6 2 April 2002 (02.04.2002) SE
- (71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).
- (71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **LARSSON, Maria** [SE/SE]; AstraZeneca R & D Sodertalje, S-151 85 Sodertalje (SE).
- (74) Agent: **ASTRAZENECA**; Glöbal Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF 2-ETHOXY-3-[4-(2-{METHANESULPHONYLOXYPHENYL}ETHOXY)PHENYL] PROPANOIC ACID



(57) Abstract: A process for the preparation of a compound of formula (I); in which R represents H or an acid protecting group which comprises reacting a compound of formula (II); in which R is as previously defined with a compound of formula (III); wherein X is a suitable leaving group in the presence of a base and using water as a diluent.



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

8 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

 Application No.
 PCT/GB 03/01395

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07C303/22 C07C309/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 62872 A (ASTRA) 9 December 1999 (1999-12-09) cited in the application page 30, line 20 - page 31, line 28	1-7
A	R.W. KIERSTEAD, ET AL.: "beta1-Selective adrenoceptor antagonists. 1. Synthesis and beta-adrenergic blocking activity of a series of binary (aryloxy)propanolamines" JOURNAL OF MEDICINAL CHEMISTRY, vol. 26, no. 11, 1983, pages 1561-1569, XP002922416 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US ISSN: 0022-2623 page 1566, right-hand column, last paragraph	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

7 October 2003

Date of mailing of the international search report

22/10/2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

English, R.

INTERNATIONAL SEARCH REPORT

Application No

PCT/Gb 03/01395

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>J.F.W. KEANA, ET AL.: "New mono- and difunctional 2,2,5,5-tetramethylpyrrolidine- and delta3-pyrroline-1-oxyl nitroxide spin labels" CANADIAN JOURNAL OF CHEMISTRY, vol. 60, no. 12, 15 June 1982 (1982-06-15), pages 1439-1447, XP002256848 NATIONAL RESEARCH COUNCIL, OTTAWA, CA page 1443, right-hand column, last paragraph</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

 Application No.
 PCT/GB 03/01395

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9962872	A	09-12-1999	AT 246674 T	15-08-2003
			AU 752261 B2	12-09-2002
			AU 4667199 A	20-12-1999
			AU 752262 B2	12-09-2002
			AU 4667299 A	20-12-1999
			BR 9910921 A	06-03-2001
			BR 9910928 A	13-02-2001
			CA 2333938 A1	09-12-1999
			CA 2334374 A1	09-12-1999
			CN 1311772 T	05-09-2001
			CN 1312795 T	12-09-2001
			DE 69910203 D1	11-09-2003
			EE 200000720 A	15-04-2002
			EE 200000725 A	17-06-2002
			EP 1084103 A1	21-03-2001
			EP 1084102 A1	21-03-2001
			HR 20000782 A1	30-06-2001
			HU 0103226 A2	28-01-2002
			HU 0103376 A2	29-05-2002
			JP 2002516899 T	11-06-2002
			JP 2002516900 T	11-06-2002
			NO 20006115 A	07-02-2001
			NO 20006116 A	02-02-2001
			NZ 508452 A	30-05-2003
			NZ 508453 A	30-06-2003
			PL 344681 A1	19-11-2001
			PL 345205 A1	03-12-2001
			WO 9962872 A1	09-12-1999
			WO 9962871 A1	09-12-1999
			SK 17682000 A3	06-08-2001
			SK 17692000 A3	10-05-2001
			TR 200003581 T2	21-06-2001
			TR 200003583 T2	21-05-2001
			TW 446696 B	21-07-2001
			US 2003027859 A1	06-02-2003
			US 6258850 B1	10-07-2001
			US 2001034371 A1	25-10-2001
			ZA 200006774 A	20-02-2002